1989
Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors.
Kacinski B, Carter D, Kohorn E, Mittal K, Bloodgood R, Donahue J, Kramer C, Fischer D, Edwards R, Chambers S. Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors. The Yale Journal Of Biology And Medicine 1989, 62: 379-92. PMID: 2556864, PMCID: PMC2589084.Peer-Reviewed Original Research
1988
High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas
Kacinski B, Carter D, Mittal K, Kohorn E, Bloodgood R, Donahue J, Donofrio L, Edwards R, Schwartz P, Chambers J, Chambers S. High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. International Journal Of Radiation Oncology • Biology • Physics 1988, 15: 823-829. PMID: 3182322, DOI: 10.1016/0360-3016(88)90113-7.Peer-Reviewed Original ResearchConceptsEndometrial currettingsDeep myometrial penetrationStage I patientsAggressive clinical behaviorHuman endometrial adenocarcinomaMicron paraffin sectionsMyometrial penetrationLocoregional spreadClinicopathologic featuresEndometrial adenocarcinomaI patientsPoor outcomeEndometrial specimensClinical behaviorInvasive adenocarcinomaBenign hyperplasiaAdenocarcinomaMalignant phenotypeParaffin sectionsM-CSFM-CSF receptorOncogene expressionProto-oncogene mRNAKi-rasPatients
1987
FMS oncogene expression may be a marker for aggressive clinical behavior in endometrial carcinoma
Kacinski B, Carter D, Mittal K, Kohorn E, Donahue J, Bloodgood R, Chambers J, Chambers S, Schwartz P. FMS oncogene expression may be a marker for aggressive clinical behavior in endometrial carcinoma. International Journal Of Radiation Oncology • Biology • Physics 1987, 13: 112-113. DOI: 10.1016/0360-3016(87)91067-4.Peer-Reviewed Original Research